Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple mye...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Richardson, Paul G., Oriol, Albert, Larocca, Alessandra, Bladé, Joan, Cavo, Michele, Rodriguez-Otero, Paula, Leleu, Xavier, Nadeem, Omar, Hiemenz, John W., Hassoun, Hani, Touzeau, Cyrille, Alegre, Adrián, Paner, Agne, Maisel, Christopher, Mazumder, Amitabha, Raptis, Anastasios, Moreb, Jan S., Anderson, Kenneth C., Laubach, Jacob P., Thuresson, Sara, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A., Mateos, María-Victoria
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078327/
https://ncbi.nlm.nih.gov/pubmed/33296242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02259
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares